Difference between revisions of "Economic evaluation"

From Testiwiki
Jump to: navigation, search
m
Line 1: Line 1:
 
{{method}}
 
{{method}}
 
{{progression class|progression=Draft}}
 
{{progression class|progression=Draft}}
 +
 +
[[op_fi:Taloudellinen_arviointi]]
  
 
== Question ==  
 
== Question ==  

Revision as of 07:03, 26 June 2014

Progression class
In Opasnet many pages being worked on and are in different classes of progression. Thus the information on those pages should be regarded with consideration. The progression class of this page has been assessed:
This page is a draft
The relevat content and structure of the page is already present, but there still is a lot of missing content.
This page needs a curator. Learn more about curating Opasnet pages.

Question

Are the incremental health effects worth the incremental costs, if a vaccine is both more effective and more expensive?

  • The health benefit of the national infant immunisation programme is assessed by the expected reduction in the annual number of invasive pneumococcal disease in the Finnish population. The health benefit or effectiveness is measured in Quality-Adjusted Life Years (QALYs).
  • The perspective of this analysis is the health care provider.


Answer

To find the most cost-effective vaccine according to the crieria described in the rationale.

Rationale

Vaccines are ranked according to their effectiveness (V1 < V2 < V3, etc.). Vaccines that are more expensive and less effective compared with at least one other alternative (strongly dominated) are excluded. Incremental cost-effectiveness ratios (ICER) are calculated for the remaining vaccines:

Failed to parse (Missing <code>texvc</code> executable. Please see math/README to configure.): ICER = \frac{(C_2-S_2) - (C_1-S_1)}{E_2-E_1},

where C is the prize of the vaccinating progranm, S is the savings in health care costs and E is the savings on QALY.

Each vaccine (ranked according to their effectiveness) is compared with the next highest ranked vaccine. The least effective vaccine is compared with doing nothing. The most cost-effective vaccine is chosen.

See also

Tendering process for pneumococcal conjugate vaccine
Parts of the assessment

Comparison criteria for vaccine   · Epidemiological modelling   · Economic evaluation

Background information

Sensitivity analysis · Replacement   · Pneumococcal vaccine products   · Finnish vaccination schedule   · Selected recent publications


Help for discussion and wiki editing

Pages in Finnish

Pneumokokkirokotteen hankinta  · Rokotteen vertailuperusteet · Epidemiologinen malli · Taloudellinen arviointi · Pneumokokkirokotteen turvallisuus


Work scheduling · Monitoring the effectiveness of the pneumococcal conjugate vaccine · Glossary of vaccine terminology